Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.2495 EUR 2.25% Market Closed
Market Cap: 31.1m EUR

EV/EBIT
Enterprise Value to EBIT

-1.1
Current
-1.9
Median
3.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-1.1
=
Enterprise Value
40.2m EUR
/
EBIT
-37.1m EUR
Market Cap EV/EBIT
FR
Gensight Biologics SA
PAR:SIGHT
31.1m EUR -1.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -208 051.8
US
Abbvie Inc
NYSE:ABBV
373.8B USD 26
US
Amgen Inc
NASDAQ:AMGN
168.4B USD 29.3
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD 27.8
US
Epizyme Inc
F:EPE
94.1B EUR -522.5
AU
CSL Ltd
ASX:CSL
121.1B AUD 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD 12.2
US
Seagen Inc
F:SGT
39.3B EUR -55.4
NL
argenx SE
XBRU:ARGX
32.9B EUR -2 339.6
EBIT Growth EV/EBIT to Growth
FR
Gensight Biologics SA
PAR:SIGHT
Average EV/EBIT: 21.8
Negative Multiple: -1.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 051.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.3
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -522.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 339.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-1.3
2-Years Forward
EV/EBIT
-1.4
3-Years Forward
EV/EBIT
-1.2